Wu Yang, Zhang Chun, Jiang Kuirong, Werner Jens, Bazhin Alexandr V, D'Haese Jan G
Department of General, Visceral, and Transplant Surgery, Ludwig-Maximilians-University Munich, Munich, Germany.
Pancreas Center and Pancreas Institute, Nanjing Medical University, Nanjing, China.
Front Oncol. 2021 Jan 14;10:621937. doi: 10.3389/fonc.2020.621937. eCollection 2020.
Pancreatic ductal adenocarcinoma (PDAC) is a gastrointestinal malignancy with a dismal clinical outcome. Accumulating evidence suggests that activated pancreatic stellate cells (PSCs), the major producers of extracellular matrix (ECM), drive the severe stromal/desmoplastic reaction in PDAC. Furthermore, the crosstalk among PSCs, pancreatic cancer cells (PCCs) as well as other stroma cells can establish a growth-supportive tumor microenvironment (TME) of PDAC, thereby enhancing tumor growth, metastasis, and chemoresistance various pathways. Recently, targeting stroma has emerged as a promising strategy for PDAC therapy, and several novel strategies have been proposed. The aim of our study is to give a profound review of the role of PSCs in PDAC progression and recent advances in stroma-targeting strategies.
胰腺导管腺癌（PDAC）是一种临床预后不佳的胃肠道恶性肿瘤。越来越多的证据表明，活化的胰腺星状细胞（PSC）是细胞外基质（ECM）的主要产生者，在PDAC中驱动严重的基质/促纤维增生反应。此外，PSC、胰腺癌细胞（PCC）以及其他基质细胞之间的相互作用可建立PDAC的生长支持性肿瘤微环境（TME），从而通过各种途径促进肿瘤生长、转移和化疗耐药性。最近，靶向基质已成为一种有前景的PDAC治疗策略，并且已经提出了几种新策略。我们研究的目的是对PSC在PDAC进展中的作用以及基质靶向策略的最新进展进行深入综述。
